

11th Stop TB Coordinating Board Meeting
29-30 November 2006, Jakarta, Indonesia
Draft Decisions/ Actions (CB 02.06)

Objectives	Outcomes
<ul style="list-style-type: none"> ▪ To review progress on TB Control in Asia. ▪ To review and endorse the Call to Stop TB in Asia. ▪ To discuss the process for the evaluation of the Stop Partnership in 2007. ▪ To discuss the XDR-TB situation and agree on the Partnership response. ▪ To discuss the World Bank Report on economic implications of TB Control in Africa. ▪ To review the structure and function of the Partnership's Working Groups. ▪ To review the process for the monitoring and implementation of the Global Plan to Stop TB (2006-2015). ▪ To discuss plans to operationalize a "TB Research Movement". ▪ To discuss progress on the task force on retooling. ▪ To discuss the Global Drug Facility Marketing and Development Plan. ▪ To discuss progress made and respond to future challenges in the collaboration between GFTAM and the Partnership. ▪ To agree on the date of the next Partners' Forum. ▪ To agree on calendar of high-level missions. 	<ul style="list-style-type: none"> ▪ Approach to strengthening TB control in Asia agreed. ▪ Call to Stop TB in Asia amended slightly and endorsed. ▪ Evaluation process of the Partnership for 2007 agreed. ▪ XDR-TB response agreed, and specific next steps determined. ▪ Next steps to finalize and disseminate World Bank report agreed. ▪ Current structure approved and improvements in the WGs processes through further accountability and less voluntarism for key positions agreed. ▪ Process for monitoring the implementation of the Global Plan established. ▪ TB Research Movement including actions needed within the Partnership endorsed. ▪ Retooling work plan for 2007 and guide on New Technologies for TB Control endorsed. ▪ GDF 3 year grant cycle with condition of additionality for programme sustainability endorsed. ▪ Agreed specific actions for GFATM and Partnership collaboration. ▪ 2008 Partners' Forum. ▪ Calendar of high-level missions endorsed and location for next CB meeting approved.

Session - presentations	Decisions	Actions	Key Docs
1) Opening Session			
Joint Opening Session with SEAR Partners			
	<ul style="list-style-type: none"> • Welcome by the Chair - Irene Koek. • UN Special Envoy - Jorge Sampaio. • WHO Assistant Director-General Asamoah Baah. • WHO/SEAR - Regional Director - Samlee Plingbangchang. • Indonesian - Minister of Health Supari. <ol style="list-style-type: none"> 1. The agenda was adopted with addition of an agenda item on staffing. 2. The report from the 10th Stop TB Coordinating Board meeting, (April 2006, Abuja) was adopted. 		2.06-1.0 2.06-1.1 2.06-1.2 2.06-1.3
2) Responding to the TB Epidemic in the South East Asia Region			
TB Control in the South East Asia Region	<ul style="list-style-type: none"> • Congratulated the Meeting of Partners for TB Control in the South-East Asia Region on the outcomes of their meeting. Reaffirmed the commitment of the Stop TB Partnership to supporting TB control in the region; • Endorsed the following actions: <ul style="list-style-type: none"> ○ Advocacy for increased and sustained domestic and external financing. ○ Promotion of comprehensive human resource development plans. ○ Advocacy for resources for technical assistance ○ Increased efforts to combat the dual epidemic of TB-HIV. ○ Increased efforts to address multi-drug resistant TB. ○ Ensuring all countries have high quality drugs and consumables. ○ Advocacy with professional societies to promote the International Standards for TB Care and Patient's Charter. ○ Development of practical and operational 	<ul style="list-style-type: none"> • Implement the key Regional actions outlined [SEAR & Partners]. • Monitor the data that is collected by technical partners on mortality in the region [WHO] . • Conduct High Level Missions (HLMs) and advocacy in the region [Sec.& Board]. 	2.06-2.0 2.06-2.1

	<p>guidance for ACSM in the Asian context.</p> <ul style="list-style-type: none"> ○ Establishment of a regional coalition, including industry, to harmonize forecasting and fulfil requirements for TB drugs, diagnostics and vaccines. ○ Ensuring that TB issues are adequately prioritized under new international and bilateral funding initiatives. 		
3) The Call to Stop TB in Asia			
The Call to Stop TB in Asia	<ul style="list-style-type: none"> ● Endorsed "The Call to Stop TB in Asia" with amendments. 	<ul style="list-style-type: none"> ● Disseminate the Call to Stop TB in Asia to ASEAN, SAARC and other key stakeholders [SEAR& Secretariat]. 	2.06-3.0 2.06-3.1
4) External Evaluation of the Stop TB Partnership 2007			
Scope and Process	<ul style="list-style-type: none"> ● Decided that the scope of the evaluation should be wide and engage with stakeholders beyond TB. Input should be secured from countries beyond the NTPs; measure and involve community; encompass research and GDF financing. ● Agreed the purpose of the evaluation was to be forward looking with clear recommendations on future action and development of the optimal structure/systems for implementation of the Global Plan. ● Decided the report on Working Groups, presented at Jakarta, be considered a key input to the evaluation. ● Approved the estimated budget range. 	<ul style="list-style-type: none"> ● Establish an evaluation Steering Group to work with the Secretariat consisting of up to five members. [AV] ● Terms of Reference of the Evaluation should be circulated electronically and approved by the Coordinating Board [AV]. 	2.06-4.0 2.06-4.1
5) XDR-TB			
Partnership Response	<ul style="list-style-type: none"> ● Affirmed the Stop TB Partnership's commitment to taking leadership against XDR, recognizing that the fight must 	<ul style="list-style-type: none"> ● Review funding requirements for global 	2.06-5.0 2.06-5.1

	<p>begin with building strong TB programs.</p> <ul style="list-style-type: none"> • Endorsed the call and committed to support resource mobilization for \$95 million of additional funding by the end of 2007 to coordinate and implement a global response to XDR-TB. • Expressed no objection to the proposal for the Infection Control Subgroup to be located under the TB-HIV Working group. • Called for stronger control of second-line drugs. • Agreed that the STB Partnership should actively engage the HIV community on this issue, including undertaking high level discussions with UNAIDS on the XDR-TB threat as well as with other HIV leaders, and issue a statement for World AIDS Day. • Stressed the need to emphasize diagnosis enhancement and to clarify what diagnostic packages are needed. 	<p>scale of the XDR-TB response, beyond needs identified for Southern Africa [WHO].</p> <ul style="list-style-type: none"> • TB/HIV in the workplace messaging developed [WEF]. • Update the Global Plan and national plans to reflect the more urgent scale-up of interventions [DOTS Expansion and MDR TB WG]. • Establish Infection Control Subgroup[TB-HIV WG]. 	<p>2.06-5.2 2.06-5.3 2.06-5.4 2.06-5.5 2.06-5.6</p>
6) Economic Implications of TB Control (2.06-6.0)			
World Bank Study	<ul style="list-style-type: none"> • Welcomed the study on the Economic Implications of TB control. • Encouraged the World Bank to ensure its clear public association with and branding of this report. • Proposed that the study be submitted to a high profile peer-reviewed journal. • After endorsement of the final version, agreed to use the study for long term advocacy in favour of increased investment in TB at events such as the G8 and African Ministerial meeting. 	<ul style="list-style-type: none"> • Finalize Study[WB]. • Plan coordinated dissemination strategy including launch in key high burden and donor capitals and the World Bank [WB, Secretariat and Partners]. 	<p>2.06-6.0 2.06-6.1</p>
7) Partnership's Working Groups			

Structure and Function	<ul style="list-style-type: none"> Decided to keep the current structure of the working groups with adjustments to be explored, based on the outcome of this report, during the upcoming evaluation. Strongly supported recommendations for greater Working Group accountability. Decided that for greater efficiency in Global Plan implementation; to examine methods to move away from voluntary positions for key Working Group officers (notably Secretariat). 	<ul style="list-style-type: none"> Facilitate first face-to-face meetings of the Working Group chairs and/or focal points to be held in conjunction with Coordinating Board meeting in Spring [Secretariat]. 	2.06-7.0
8) <u>Monitoring and Evaluation</u>			
Implementation of the Global Plan	<ul style="list-style-type: none"> Strongly endorsed the need to establish a monitoring system for the Global Plan Advised that less formal, biannual updates should be made to the Coordinating Board that reporting should rely on and not duplicate regional progress reports. An independent review of the reports should focus on substantive impact indicators rather than process indicators. 	<ul style="list-style-type: none"> Appoint a focal point for monitoring and evaluation [Working Group Chairs]. Develop a simplified and shortened standard template [Secretariat] Present an annual progress report to the Coordinating Board. [Secretariat and WG Chairs] Create a small sub-committee to review Working Group and Regional reports [Secretariat & Board]. 	2.06-8.0 2.06-8.1 2.06-8.2
9) TB Research			
	<ul style="list-style-type: none"> Endorsed proposals to track resource available for R&D on a regular basis. Agreed that the Partnership would undertake a research mapping exercise/landscape analysis Instructed that the external evaluation should examine how 	<ul style="list-style-type: none"> Secretariat to tender for research resource tracking, in coordination with other resource tracking activities 	2.06-9.0 2.06-9.1 2.06-9.2 2.06-9.3 2.06-9.4

	the partnership should approach the organizational aspects of research including the need for an overarching research plan for TB connected to strategic targets and for how basic research should be included in the Partnership framework.	[AV & LB].	
10) Task Force on Retooling			
Guideline and Work Plan	<ul style="list-style-type: none"> • Endorsed the guide “New Technologies for TB Control: A Guide for their Adoption, Introduction and Implementation”; • Endorsed the 2007 retooling work plan. 	<ul style="list-style-type: none"> • Identify potential sources of funding to fulfill the Task Force budget of US\$150 000 for 2007. [Secretariat/Task Force and Board members]. • Private sector constituency to be represented on the Task Force, with other relevant constituencies included as appropriate [Task Force]. 	2.06-10.0 2.06-10.1 2.06-10.2 2.06-10.3
11) TB Diagnostics			
Market Survey	<ul style="list-style-type: none"> • Congratulated FIND and TDR on the publication of the Diagnostics for tuberculosis; global demand and market potential. 	<ul style="list-style-type: none"> • Distribute copy of the study to CB participants [FIND]. 	2.06-11.0 2.06-11.1
12) Global Drug Facility			
Sustainability Plan	<ul style="list-style-type: none"> • Decided to maintain a GDF grant service with a 3 year cycle. • Agreed to make GDF grants conditional on progressively increased budget lines for TB drugs. • Decided that the external evaluation should measure the extent GDF support has leveraged or replaced domestic and other funding sources. 	<ul style="list-style-type: none"> • Introduce a Financial Sustainability process for countries to guide the increase of budgets for TB drugs [GDF]. • Strengthen the current GDF/GFATM collaboration with the main purpose of increasing the number of GFATM grantees using 	2.06-12.0 2.06-12.1 2.06-12.2 2.06-12.3

		GDF [GDF & GFATM].	
13) Global Fund			
Progress and Challenges	<ul style="list-style-type: none"> • Called on the GFATM to ensure broader TB representation in GFATM meetings. • Decided to engage with GFATM in discussions on the provision of Technical Assistance (based on the TB TEAM model), GDF/drug procurement and on funds flow bottlenecks. • Instructed partners to support the implementation of existing grants and to provide technical support to round 7 applications. • Agreed that the 2 year MOU between the Partnership and GFATM (signed in 2005) is a valuable tool for collaboration. 	<ul style="list-style-type: none"> • Pursue the goal of a seat for the Stop TB Partnership on the GFATM Board [Sec]. • Facilitate reprogramming for work related to XDR-TB [GFATM]. • Facilitate high-level delegation to the new GFATM Executive Director, once appointed [Sec]. • Negotiate renewal of Partnership-GFATM MOU in 2007 [Sec]. 	2.06-13.0 2.06-13.1 2.06-13.2
14) The 2008 Partners' Forum			
	<ul style="list-style-type: none"> • Decided to approve the planning and realization of a Partner's Forum for 2008. 	<ul style="list-style-type: none"> • Prepare a proposal with options for consideration by the Board [Sec]. • Establish a Steering Committee from among Board Members to guide the Partners' Forum process [Sec]. 	2.06-14.0
15) Working Group Activities			
Update	<ul style="list-style-type: none"> • Noted the changes to structure of the Working Group on Advocacy, Communication and Social Mobilization. 	<ul style="list-style-type: none"> • None 	2.06-15.0 2.06-15.1 2.06-15.2
16) Coordinating Board Meetings 2007 and High Level Missions Calendar			

Germany South Africa or Russia	<ul style="list-style-type: none"> • Endorsed the date and location for the Spring 2007 Coordinating Board meeting (Berlin, 18-19 April 2007). • Endorsed the calendar of high level missions. 	<ul style="list-style-type: none"> • Commence planning for Berlin CB meeting [Sec]. • Implement the HLM calendar [Sec]. 	2.06-16.0 2.06-16.1
END			